 PART 1: Closed to accrual as of 8252015 ARM A1: Patients receive dabrafenib orally PO twice daily BID and trametinib PO once daily QD for 25 days. Patients then receive ipilimumab intravenously IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. 